Program
benmelstobart
Also written as “TQB2450”, “TQB2450 injection” and “Benmelstobart injection combined with Anlotinib hydrochloride capsule”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Endometrial Neoplasms · Triple Negative Breast Neoplasms · Sarcoma, Alveolar Soft Part, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 339 open or running | phase 3since Jan 16, 2020 | Feb 26, 2018 | Dec 2027phase 3 · NCT06475599 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 19 studies since Feb 26, 2018.
- May 17, 2021Phase 2 study in Nasopharyngeal CarcinomaNCT04895345 · 25 enrolled · China
- Jul 13, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04964479 · 375 enrolled · China
- Nov 23, 2021Phase 3 study in Recurrent Platinum-resistant Ovarian CancerNCT05145218 · 405 enrolled · China
- Apr 20, 2022Phase 3 study in Advanced Non-squamous Non-small Cell Lung CancerNCT05346952 · 390 enrolled · China
- Nov 21, 2022Phase 2 study in Advanced Solid TumorNCT05645315 · 127 enrolled · China
- Dec 20, 2022Phase 3 study in Advanced Squamous Non-Small Cell Lung CarcinomaNCT05718167 · 570 planned · China
- Jun 13, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05913089 · 58 planned · China
- Oct 31, 2023Phase 1 study in Solid TumorNCT06116240 · 135 enrolled · China
- Jun 17, 20242 phase 3 studiesNCT06469879, NCT06475599
- Jul 4, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06496490 · 270 planned · China
- Jan 6, 2025Phase 2 study in Gastroesophageal AdenocarcinomaNCT06767800 · 204 planned · China
- Mar 19, 2025Phase 2 study in Extensive Stage Small Cell Lung CancerNCT06897579 · 40 enrolled · China
- Apr 17, 2026Phase 2 study in Sarcoma, Alveolar Soft PartNCT07548177 · 33 planned · China
- Nov 16, 2026Primary completion moved from 2027-11 to 2028-12Date moved laterphase 2 · +13 months · NCT07548177
Ahead
- Dec 2027Primary completion: phase 3 study in Endometrial NeoplasmsNCT06475599
- Dec 2028Primary completion: phase 2 study in Sarcoma, Alveolar Soft PartNCT07548177
TargetBeta
“A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule
Other programs on CD274
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| durvalumabrule | AstraZeneca | phase 4 | 102 |
| adebrelimabrule | Jiangsu HengRui Medicine | phase 3 | 51 |
| pumitamig | BioNTech | phase 3 | 34 |
| retlirafusp alfarule | Jiangsu HengRui Medicine | phase 3 | 20 |
| Anti-PD-L1 Antibody-drug Conjugate HLX43 | Fosun Pharma | phase 3 | 17 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| socazolimabrule | Lee's Pharmaceutical | phase 3 | 9 |
| acasunlimabrule | Genmab | phase 3 | 6 |
| sotiburafusp alfarule | huabo-biopharm-co-ltd | phase 3 | 5 |
| fetrastobart vedotin | Pfizer | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07548177Sarcoma, Alveolar Soft Part · China | 2 | Recruiting | Dec 2028 | 33 |
| NCT06897579Extensive Stage Small Cell Lung Cancer · China | 2 | Terminated | Apr 15, 2026 | 40 |
| NCT06767800Gastroesophageal Adenocarcinoma · China | 2 | Recruiting | Sep 2026 | 204 |
| NCT06496490Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Jun 2026 | 270 |
| NCT06475599Endometrial Neoplasms · China | 3 | Not yet recruiting | Dec 2027 | 420 |
| NCT06469879Small Cell Lung Cancer Limited Stage · China | 3 | Not yet recruiting | Sep 2026 | 358 |
| NCT06116240Solid Tumor · China | 1 | Active, not recruiting | Dec 2023 | 135 |
| NCT05913089Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Jun 2026 | 58 |
| NCT05718167Advanced Squamous Non-Small Cell Lung Carcinoma · China | 3 | Not yet recruiting | Oct 2024 | 570 |
| NCT05645315Advanced Solid Tumor · China | 2 | UNKNOWN | Dec 2023 | 127 |
| NCT05346952Advanced Non-squamous Non-small Cell Lung Cancer · China | 3 | UNKNOWN | Dec 2023 | 390 |
| NCT05145218Recurrent Platinum-resistant Ovarian Cancer · China | 3 | UNKNOWN | Oct 2024 | 405 |
| NCT04964479Carcinoma, Non-Small-Cell Lung · China | 3 | UNKNOWN | Dec 2022 | 375 |
| NCT04895345Nasopharyngeal Carcinoma · China | 2 | Completed | Apr 29, 2024 | 25 |
| NCT04809142Advanced Biliary Cancer · China | 3 | UNKNOWN | Mar 18, 2022 | 392 |
| NCT04623333Recurrence · China | 2 | UNKNOWN | Dec 31, 2022 | 80 |
| NCT04574284Advanced Endometrial Cancer · China | 2 | Completed | Nov 9, 2023 | 170 |
| NCT04523272Advanced Renal Cancer · China | 3 | Active, not recruiting | Jun 2025 | 528 |
| NCT04405505Triple Negative Breast Neoplasms · China | 3 | UNKNOWN | Jul 1, 2022 | 332 |
| NCT04325763Carcinoma, Non-Small-Cell Lung · China | 3 | UNKNOWN | Dec 2022 | 315 |
| NCT04306926Advanced Oligometastatic Non-small Cell Lung Cancer · China | 2 | UNKNOWN | Oct 31, 2022 | 59 |
| NCT04236362Gynecological Cancer · China | 2 | UNKNOWN | Dec 31, 2021 | 90 |
| NCT04234607Extensive Small Cell Lung Cancer · China | 3 | UNKNOWN | Dec 2022 | 738 |
| NCT04002622Recurrence · China | 2 | Terminated | Jan 21, 2021 | 1 |
| NCT03996408Advanced Cholangiocarcinoma · China | 2 | UNKNOWN | Dec 31, 2020 | 42 |
| NCT03991975Advanced Acral Malignant Melanoma · China | 2 | UNKNOWN | Mar 31, 2020 | 42 |
| NCT03983928Lung Neoplasms · China | 2 | UNKNOWN | Oct 31, 2020 | 30 |
| NCT03910127Carcinoma, Non-Small-Cell Lung · China | 1 | UNKNOWN | Dec 31, 2020 | 90 |
| NCT03897283Advanced Solid Tumors · China | 1 | UNKNOWN | Jun 30, 2020 | 22 |
| NCT03855358Triple Negative Breast Neoplasms · China | 1 | UNKNOWN | Jun 30, 2020 | 30 |
| NCT03825705Carcinoma, Hepatocellular · China | 2 | UNKNOWN | Jan 1, 2021 | 60 |
| NCT03800706Safety and Effectiveness · China | 2 | UNKNOWN | Jun 30, 2021 | 85 |
| NCT03460457Neoplasms | 1 | UNKNOWN | Mar 15, 2019 | 50 |
How it is read
Names in the registry
- “TQB2450”, 18 entries
- “TQB2450 injection”, 4 entries
- “Benmelstobart injection combined with Anlotinib hydrochloride capsule”, 1 entry
- “Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule”, 1 entry
- “TQB2102 for injection combined with Benmelstobart injection”, 1 entry
Codes read as this program: TQB2450.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 8 studies
- Small Cell Lung Carcinoma, 3 studies
- Endometrial Neoplasms, 2 studies
- Triple Negative Breast Neoplasms, 2 studies
- Sarcoma, Alveolar Soft Part, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.